David B Clifford

List of Publications by Year
in descending order

251	21,579	13099	10158
papers	citations	68	140
		h-index	g-index

256	256	256	13883
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. Brain, 2022, 145, 2206-2213.	7.6	1
2	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
3	Post-acute sensory neurological sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: the COVID-PN observational cohort study. Pain, 2022, 163, 2398-2410.	4.2	8
4	The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells. Journal of Neuroimmunology, 2022, 367, 577860.	2.3	6
5	Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum. American Journal of Medical Genetics, Part A, 2021, 185, 15-25.	1.2	15
6	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis and Rheumatology, 2021, 73, 12-20.	5.6	25
7	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis Care and Research, 2021, 73, 1-9.	3.4	27
8	Cohort study protocol to characterize the incidence and severity of neuropathic pain in patients with severe acute respiratory syndrome coronavirus 2 infection. Pain Reports, 2021, 6, e925.	2.7	6
9	IGG4-Related Disease in the Skull Base and Calvarium: A Systematic Review and Presentation of Two Cases. , 2021, 82, .		1
10	Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy. Pain Medicine, 2021, 22, 1850-1856.	1.9	3
11	Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy. Neurology, 2021, 97, e156-e165.	1.1	5
12	Imaging Synaptic Architecture in Human Immunodeficiency Virus: Checkpoint for Brain Function?. Clinical Infectious Diseases, 2021, 73, 1412-1413.	5.8	0
13	IgG4-Related Disease of the Skull and Skull Baseâ€“A Systematic Review and Report of Two Cases. World Neurosurgery, 2021, 150, 179-196.e1.	1.3	10
14	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
15	Hope for progressive multifocal leukoencephalopathy. Lancet Neurology, The, 2021, 20, 589-591.	10.2	0
16	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, 2021, 72, e1-e48.	5.8	174
17	The devil's details: pathological correlates of progressive multifocal leukoencephalopathy magnetic resonance imaging. European Journal of Neurology, 2021, , .	3.3	0
18	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, 2021, 72, 1-8.	5.8	66

#	Article	IF	Citations
19	Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. Journal of the International Neuropsychological Society, 2020, 26, 147-162.	1.8	15
20	Thinking About Getting Older With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2020, 70, 2649-2651.	5.8	0
21	Checkpoint therapy for progressive multifocal leukoencephalopathy: pointless?. European Journal of Neurology, 2020, 27, 2114-2116.	3.3	2
22	Interleukin-15 superagonist (N-803) treatment of PML and JCV in a postâ€“allogeneic hematopoietic stem cell transplant patient. Blood Advances, 2020, 4, 2387-2391.	5.2	11
23	Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration. Neurotherapeutics, 2020, 17, 955-965.	4.4	17
24	Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. Annals of Clinical and Translational Neurology, 2020, 7, 1166-1173.	3.7	12
25	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€“Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755.	9.0	6
26	Herpesvirus Infections and Risk of Parkinsonâ€™s Disease. Neurodegenerative Diseases, 2020, 20, 97-103.	1.4	12
27	Higher iron stores and the HFE 187C>G variant delay onset of peripheral neuropathy during combination antiretroviral therapy. PLoS ONE, 2020, 15, e0239758.	2.5	3
28	Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV,the, 2019, 6, e456-e462.	4.7	15
29	Dosing interval of natalizumab in MS. Neurology, 2019, 93, 655-656.	1.1	0
30	High alert!. Multiple Sclerosis Journal, 2019, 25, 1685-1685.	3.0	1
31	Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. Journal of the International Neuropsychological Society, 2019, 25, 507-519.	1.8	28
32	Progressive multifocal leukoencephalopathy treated with nivolumab. Journal of NeuroVirology, 2019, 25, 284-287.	2.1	40
33	Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy. Aids, 2019, 33, 475-481.	2.2	44
34	Effects of comorbidity burden and age on brain integrity in HIV. Aids, 2019, 33, 1175-1185.	2.2	35
35	Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection. Molecular Neurobiology, 2019, 56, 3808-3818.	4.0	26
36	White matter damage, neuroinflammation, and neuronal integrity in HAND. Journal of NeuroVirology, 2019, 25, 32-41.	2.1	77

#	Article	IF	Citations
37	Is successful HIV therapy a Pyrrhic victory for the brain?. Journal of Clinical Investigation, 2019, 129, 3052-3053.	8.2	2
38	Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurology, The, 2018, 17, 467-480.	10.2	147
39	Progressive multifocal leukoencephalopathy. Neurology, 2018, 90, 255-256.	1.1	2
40	Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States. Journal of the International Neuropsychological Society, 2018, 24, 163-175.	1.8	29
41	Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2018, 34, 942-949.	1.1	4
42	Progressive multifocal leukoencephalopathy with extended natalizumab dosing. Neurology: Clinical Practice, 2018, 8, e12-e14.	1.6	9
43	A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. Drug Safety, 2018, 41, 807-816.	3.2	5
44	Characterization of Cellular Immune Responses in Thai Individuals With and Without HIV-Associated Neurocognitive Disorders. AIDS Research and Human Retroviruses, 2018, 34, 685-689.	1.1	7
45	Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. JAMA Neurology, 2018, 75, 1546.	9.0	247
46	Genomeâ€wide association study of HIVâ€associated neurocognitive disorder (HAND): A CHARTER group study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 413-426.	1.7	26
47	HIV-associated neurocognitive disorder. Current Opinion in Infectious Diseases, 2017, 30, 117-122.	3.1	62
48	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
49	Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. Journal of Neuroinflammation, 2017, 14, 72.	7.2	30
50	Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining â€œsymptomaticâ€•versus â€œasymptomaticâ€•HAND. Journal of NeuroVirology, 2017, 23, 67-78.	2.1	25
51	The DIANâ€TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimer's and Dementia, 2017, 13, 8-19.	0.8	230
52	A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance?. Multiple Sclerosis Journal, 2017, 23, 934-936.	3.0	4
53	JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. Journal of NeuroVirology, 2017, 23, 141-146.	2.1	16
54	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0

#	Article	IF	Citations
55	F4â€03â€02: The Dominantly Inherited Alzheimer Network Trials Unit. Alzheimer's and Dementia, 2016, 12, P326.	0.8	0
56	Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls. Neurotherapeutics, 2016, 13, 571-581.	4.4	4
57	Apolipoprotein E Îµ4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. Journal of NeuroVirology, 2016, 22, 607-614.	2.1	13
58	The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Research and Human Retroviruses, 2016, 32, 636-647.	1.1	34
59	Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. Journal of NeuroVirology, 2016, 22, 479-487.	2.1	26
60	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. Journal of Infectious Diseases, 2016, 213, 1065-1073.	4.0	31
61	Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. Journal of NeuroVirology, 2016, 22, 170-178.	2.1	112
62	Lower CSF A? is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Current HIV Research, 2016, 14, 324-330.	0.5	4
63	Nemesis of neglected neurosarcoidosis. Annals of Clinical and Translational Neurology, 2015, 2, 947-948.	3.7	3
64	Neurological immune reconstitution inflammatory response. Current Opinion in Neurology, 2015, 28, 295-301.	3.6	29
65	Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain, 2015, 156, 731-739.	4.2	31
66	Factors Associated With the Onset and Persistence of Postâ€“Lumbar Puncture Headache. JAMA Neurology, 2015, 72, 325.	9.0	59
67	Association between brain volumes and HAND in cART-naÃ¯ve HIV+ individuals from Thailand. Journal of NeuroVirology, 2015, 21, 105-112.	2.1	18
68	Patterns of peripheral neuropathy in ART-naÃ¯ve patients initiating modern ART regimen. Journal of NeuroVirology, 2015, 21, 210-218.	2.1	17
69	Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clinical Infectious Diseases, 2015, 61, 1476-1484.	5.8	27
70	Reply to Haddow, et al.. Clinical Infectious Diseases, 2015, 60, 1442-3.	5.8	0
71	Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. Journal of NeuroVirology, 2015, 21, 637-644.	2.1	80
72	Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology, 2015, 84, 241-250.	1.1	40

#	Article	IF	Citations
73	Whippleâ€™s Disease Masquerades as Dementia With Lewy Bodies. Alzheimer Disease and Associated Disorders, 2015, 29, 85-89.	1.3	7
74	CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. Journal of NeuroVirology, 2015, 21, 559-567.	2.1	36
75	Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study. Clinical Infectious Diseases, 2015, 60, 473-480.	5.8	326
76	Progressive multifocal leukoencephalopathy therapy. Journal of NeuroVirology, 2015, 21, 632-636.	2.1	37
77	Genetic Variation in Iron Metabolism Is Associated with Neuropathic Pain and Pain Severity in HIV-Infected Patients on Antiretroviral Therapy. PLoS ONE, 2014, 9, e103123.	2.5	29
78	Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. Journal of NeuroVirology, 2014, 20, 620-626.	2.1	24
79	Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. Journal of NeuroVirology, 2014, 20, 603-611.	2.1	11
80	The relationship of CPE to HIV dementia. Neurology, 2014, 83, 109-110.	1.1	10
81	The Cerebrospinal Fluid HIV Risk Score for Assessing Central Nervous System Activity in Persons With HIV. American Journal of Epidemiology, 2014, 180, 297-307.	3.4	35
82	Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology, 2014, 82, 2055-2062.	1.1	255
83	Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. Journal of NeuroVirology, 2014, 20, 304-308.	2.1	14
84	Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS: Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort. Journal of HIV/AIDS and Social Services, 2014, 13, 8-25.	0.7	6
85	Randomized Trial of Central Nervous Systemâ€“Targeted Antiretrovirals for HIV-Associated Neurocognitive Disorder. Clinical Infectious Diseases, 2014, 58, 1015-1022.	5.8	110
86	Neuroinfectious disease. Neurology: Clinical Practice, 2014, 4, 187-189.	1.6	0
87	Bacterial Brain Abscess. Neurohospitalist, The, 2014, 4, 196-204.	0.8	122
88	FTS-03-03: THE DIAN-TU. , 2014, 10, P247-P247.		0
89	Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. Journal of NeuroVirology, 2013, 19, 393-401.	2.1	38
90	A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. Journal of NeuroVirology, 2013, 19, 351-358.	2.1	138

#	Article	IF	Citations
91	Tumefactive demyelination in a patient with human immunodeficiency virus. Journal of NeuroVirology, 2013, 19, 265-269.	2.1	3
92	Susac syndrome in a patient with human immunodeficiency virus infection. Journal of NeuroVirology, 2013, 19, 270-273.	2.1	3
93	Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. Journal of NeuroVirology, 2013, 19, 137-143.	2.1	19
94	Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2013, 19, 150-156.	2.1	57
95	The Alzheimerâ€™s disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. Journal of NeuroVirology, 2013, 19, 109-116.	2.1	54
96	HIV-associated neurocognitive disorder. Lancet Infectious Diseases, The, 2013, 13, 976-986.	9.1	501
97	Natalizumab. JAMA Neurology, 2013, 70, 172.	9.0	108
98	Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. Journal of NeuroVirology, 2013, 19, 557-564.	2.1	45
99	Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. Journal of Antimicrobial Chemotherapy, 2013, 68, 684-689.	3.0	34
100	Etravirine in CSF is highly protein bound. Journal of Antimicrobial Chemotherapy, 2013, 68, 1161-1168.	3.0	25
101	CNSâ€“Immune Reconstitution Inflammatory Syndrome in the Setting of HIV Infection, Part 2: Discussion of Neuroâ€“Immune Reconstitution Inflammatory Syndrome with and without Other Pathogens. American Journal of Neuroradiology, 2013, 34, 1308-1318.	2.4	39
102	CNSâ€“Immune Reconstitution Inflammatory Syndrome in the Setting of HIV Infection, Part 1: Overview and Discussion of Progressive Multifocal Leukoencephalopathyâ€“Immune Reconstitution Inflammatory Syndrome and Cryptococcalâ€“Immune Reconstitution Inflammatory Syndrome. American Journal of Neuroradiology, 2013, 34, 1297-1307.	2.4	65
103	PML diagnostic criteria. Neurology, 2013, 80, 1430-1438.	1.1	574
104	Experience and Challenges Presented by a Multicenter Crossover Study of Combination Analgesic Therapy for the Treatment of Painful HIV-Associated Polyneuropathies. Pain Medicine, 2013, 14, 1039-1047.	1.9	23
105	HIV DNA Reservoir Increases Risk for Cognitive Disorders in cART-NaÃ¯ve Patients. PLoS ONE, 2013, 8, e70164.	2.5	82
106	Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2012, 56, 1985-1989.	3.2	14
107	Diagnosing Symptomatic HIV-Associated Neurocognitive Disorders: Self-Report Versus Performance-Based Assessment of Everyday Functioning. Journal of the International Neuropsychological Society, 2012, 18, 79-88.	1.8	99
108	A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-Associated Distal Sensory Polyneuropathy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 126-133.	2.1	82

#	Article	IF	Citations
109	¹¹C-PiB Imaging of Human Immunodeficiency Virusâ€“Associated Neurocognitive Disorder. Archives of Neurology, 2012, 69, 72.	4.5	72
110	Relationship of Medication Management Test-Revised (MMT-R) Performance to Neuropsychological Functioning and Antiretroviral Adherence in Adults with HIV. AIDS and Behavior, 2012, 16, 2286-2296.	2.7	34
111	HIV peripheral neuropathy progression: protection with glucose-lowering drugs?. Journal of NeuroVirology, 2012, 18, 428-433.	2.1	16
112	Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. Journal of NeuroVirology, 2012, 18, 511-520.	2.1	24
113	Health-Related Quality of Life â€˜Well-Being' in HIV Distal Neuropathic Pain is More Strongly Associated with Depression Severity than with Pain Intensity. Psychosomatics, 2012, 53, 380-386.	2.5	40
114	Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. Journal of NeuroVirology, 2012, 18, 81-90.	2.1	15
115	Antiepileptic drug selection for people with HIV/AIDS: Evidenceâ€based guidelines from the ILAE and AAN. Epilepsia, 2012, 53, 207-214.	5.1	47
116	Lifetime suicidal ideation and attempt are common among HIV+ individuals. Journal of Affective Disorders, 2012, 136, 993-999.	4.1	75
117	Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 505-522.	1.3	143
118	Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. Journal of Clinical Virology, 2011, 52, 328-332.	3.1	11
119	Family History of Dementia Predicts Worse Neuropsychological Functioning Among HIV-Infected Persons. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 316-323.	1.8	10
120	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758.	10.2	247
121	Performances on the CogState and Standard Neuropsychological Batteries Among HIV Patients Without Dementia. AIDS and Behavior, 2011, 15, 1902-1909.	2.7	52
122	HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of NeuroVirology, 2011, 17, 3-16.	2.1	1,327
123	Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals. Journal of NeuroVirology, 2011, 17, 17-25.	2.1	26
124	Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. Journal of NeuroVirology, 2011, 17, 166-175.	2.1	29
125	Clinical factors related to brain structure in HIV: the CHARTER study. Journal of NeuroVirology, 2011, 17, 248-57.	2.1	158
126	Progressive multifocal leukoencephalopathy in transplant recipients. Annals of Neurology, 2011, 70, 305-322.	5.3	152

#	Article	IF	Citations
127	Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. Journal of Antimicrobial Chemotherapy, 2011, 66, 354-357.	3.0	82
128	JC Virus Antibody and Viremia as Predictors of Progressive Multifocal Leukoencephalopathy in Human Immunodeficiency Virus-1â€“Infected Individuals. Clinical Infectious Diseases, 2011, 53, 711-715.	5.8	52
129	Peripheral neuropathy in HIV: prevalence and risk factors. Aids, 2011, 25, 919-928.	2.2	171
130	Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis. Archives of Neurology, 2011, 68, 1156.	4.5	244
131	Role of CD4 ⁺ and CD8 ⁺ T-Cell Responses against JC Virus in the Outcome of Patients with Progressive Multifocal Leukoencephalopathy (PML) and PML with Immune Reconstitution Inflammatory Syndrome. Journal of Virology, 2011, 85, 7256-7263.	3.4	116
132	Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 921-928.	1.2	46
133	Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology, 2011, 77, 1061-1067.	1.1	209
134	Lessons from the clinic: A case of natalizumab-associated PML. Neurology, 2011, 76, 574-574.	1.1	26
135	Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 326-334.	1.3	17
136	Vicriviroc and Peripheral Neuropathy: Results from AIDS Clinical Trials Group 5211. HIV Clinical Trials, 2010, 11, 51-58.	2.0	4
137	NeuroAIDS in Africa. Journal of NeuroVirology, 2010, 16, 189-202.	2.1	42
138	Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurology, The, 2010, 9, 438-446.	10.2	604
139	PML: underdiagnosed in MS patients on natalizumab â€“ Authors' reply. Lancet Neurology, The, 2010, 9, 564-565.	10.2	0
140	Viral Escape in Cerebrospinal Fluidâ€”An Achilles Heel of HIV Therapy?. Journal of Infectious Diseases, 2010, 202, 1768-1769.	4.0	11
141	African Mitochondrial DNA Subhaplogroups and Peripheral Neuropathy during Antiretroviral Therapy. Journal of Infectious Diseases, 2010, 201, 1703-1707.	4.0	38
142	Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virusâ€“Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy. Archives of Neurology, 2010, 67, 552.	4.5	347
143	Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy. Multiple Sclerosis Journal, 2010, 16, 749-753.	3.0	8
144	Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1. Antimicrobial Agents and Chemotherapy, 2010, 54, 5156-5160.	3.2	63

#	Article	IF	Citations
145	Pregabalin for painful HIV neuropathy. Neurology, 2010, 74, 413-420.	1.1	185
146	HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology, 2010, 75, 2087-2096.	1.1	2,036
147	Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nature Reviews Neurology, 2010, 6, 667-679.	10.1	191
148	Neurologic Presentations of Sarcoidosis. Neurologic Clinics, 2010, 28, 185-198.	1.8	47
149	Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab. New England Journal of Medicine, 2009, 361, 1075-1080.	27.0	190
150	Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s). HIV Clinical Trials, 2009, 10, 343-355.	2.0	100
151	CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology, 2009, 73, 1982-1987.	1.1	156
152	Determinants of survival in progressive multifocal leukoencephalopathy. Neurology, 2009, 73, 1551-1558.	1.1	154
153	HIV Subtype D Is Associated with Dementia, Compared with Subtype A, in Immunosuppressed Individuals at Risk of Cognitive Impairment in Kampala, Uganda. Clinical Infectious Diseases, 2009, 49, 780-786.	5.8	129
154	HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Current Neurology and Neuroscience Reports, 2008, 8, 455-461.	4.2	47
155	Natalizumab and PML: a risky business?. Gut, 2008, 57, 1347-1349.	12.1	14
156	Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System. Archives of Neurology, 2008, 65, 65.	4.5	777
157	The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics Journal, 2008, 8, 71-77.	2.0	56
158	Simplification of the Research Diagnosis of HIV-Associated Sensory Neuropathy. HIV Clinical Trials, 2008, 9, 434-439.	2.0	15
159	HIV-associated neurocognitive disease continues in the antiretroviral era. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2008, 16, 94-8.	2.9	51
160	Frequency and Phenotype of JC Virus-Specific CD8 + T Lymphocytes in the Peripheral Blood of Patients with Progressive Multifocal Leukoencephalopathy. Journal of Virology, 2007, 81, 3361-3368.	3.4	59
161	Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial. PLOS Clinical Trials, 2007, 2, e13.	3.5	46
162	Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. HIV Clinical Trials, 2007, 8, 437-446.	2.0	30

#	Article	IF	Citations
163	Histoplasmoma: Isolated central nervous system infection with Histoplasma capsulatum in a patient with AIDS. Clinical Neurology and Neurosurgery, 2007, 109, 176-181.	1.4	17
164	HIV-associated cognitive impairment in sub-Saharan Africaâ€"the potential effect of clade diversity. Nature Clinical Practice Neurology, 2007, 3, 436-443.	2.5	49
165	A Randomized Trial Evaluating Prosaptideâ„¢ for HIV-Associated Sensory Neuropathies: Use of an Electronic Diary to Record Neuropathic Pain. PLoS ONE, 2007, 2, e551.	2.5	36
166	HIV-associated neuromuscular weakness syndrome in Brazil: report of the two first cases. Arquivos De Neuro-Psiquiatria, 2007, 65, 848-851.	0.8	5
167	Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurology, The, 2007, 6, 431-441.	10.2	331
168	Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. Journal of NeuroVirology, 2007, 13, 67-72.	2.1	45
169	The Role of Cohort Studies in Drug Development: Clinical Evidence of Antiviral Activity of Serotonin Reuptake Inhibitors and HMG-CoA Reductase Inhibitors in the Central Nervous System. Journal of NeuroImmune Pharmacology, 2007, 2, 120-127.	4.1	38
170	Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. Aids, 2006, 20, 1503-1513.	2.2	53
171	Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases, 2006, 42, 401-407.	5.8	208
172	Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine, 2006, 354, 924-933.	27.0	744
173	The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. Aids, 2005, 19, S64-S71.	2.2	65
174	Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. Aids, 2005, 19, 1341-1349.	2.2	129
175	Clinical validation of the NeuroScreen. Journal of NeuroVirology, 2005, 11, 503-511.	2.1	65
176	Pharmacogenetics of Longâ€Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study. Journal of Infectious Diseases, 2005, 192, 1931-1942.	4.0	232
177	Genotyping of Toxoplasma gondii Strains from Immunocompromised Patients Reveals High Prevalence of Type I Strains. Journal of Clinical Microbiology, 2005, 43, 5881-5887.	3.9	185
178	Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. Annals of Internal Medicine, 2005, 143, 714.	3.9	226
179	HIV-associated neuromuscular weakness syndrome. Aids, 2004, 18, 1403-1412.	2.2	53
180	Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids, 2004, 18, 2391-400.	2.2	429

#	Article	IF	Citations
181	Challenges for Clinical Trials to Treat Progressive Multifocal Leukoencephalopathy. Journal of NeuroVirology, 2003, 9, 68-72.	2.1	5
182	Effects of fructose-1,6-bisphosphate on morphological and functional neuronal integrity in rat hippocampal slices during energy deprivation. Neuroscience, 2003, 116, 465-475.	2.3	13
183	Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 59-62.	3.0	61
184	The Evolving Face of Human Immunodeficiency Virus-Related Progressive Multifocal Leukoencephalopathy: Defining a Consensus Terminology. Journal of NeuroVirology, 2003, 9, 88-92.	2.1	11
185	A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. Aids, 2002, 16, 1791-1797.	2.2	183
186	A randomized clinical trial of CPI-1189 for HIV-associated cognitiveâ€“motor impairment. Neurology, 2002, 59, 1568-1573.	1.1	77
187	AIDS dementia. Medical Clinics of North America, 2002, 86, 537-550.	2.5	26
188	Challenges for clinical trials on progressive multifocal leukoencephalopathy. Journal of NeuroVirology, 2001, 7, 350-352.	2.1	2
189	HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. Aids, 2001, 15, 747-751.	2.2	47
190	BK Virus: A Clinical Review. Clinical Infectious Diseases, 2001, 33, 191-202.	5.8	237
191	Human Immunodeficiency Virusâ€“Associated Dementia. Archives of Neurology, 2000, 57, 321.	4.5	56
192	HIV-Associated Dementia. Science, 2000, 288, 439d-439.	12.6	54
193	Opportunistic Viral Infections in the Setting of Human Immunodeficiency Virus. Seminars in Neurology, 1999, 19, 185-192.	1.4	22
194	HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology, 1999, 52, 623-623.	1.1	245
195	Notes Progressive Multifocal Leukoencephalopathy in Patients with AIDS Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 1999, 28, 1152-1154.	5.8	88
196	Central neurologic complications of HIV infection. Current Infectious Disease Reports, 1999, 1, 187-191.	3.0	6
197	Focal brain lesions in people with HIV. Current Treatment Options in Neurology, 1999, 1, 167-172.	1.8	6
198	Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Annals of Neurology, 1999, 45, 816-820.	5.3	102

#	Article	IF	Citations
199	Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. Aids, 1999, 13, 1677-1685.	2.2	131
200	Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. American Journal of Neuroradiology, 1999, 20, 1896-906.	2.4	108
201	Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1998, 338, 1345-1351.	27.0	343
202	NEUROLOGIC COMPLICATIONS OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION. Neurologist, 1998, 4, 54-65.	0.7	4
203	Stable neurological function in subjects treated with 23-dideoxyinosine. Journal of NeuroVirology, 1997, 3, 233-240.	2.1	9
204	Nitric oxide inhibitors attenuate ischemic degeneration in the CA1 region of rat hippocampal slices. Neuroscience Letters, 1996, 210, 157-160.	2.1	24
205	Cytomegalovirus Encephalitis. Annals of Internal Medicine, 1996, 125, 577.	3.9	191
206	Magnetic resonance brain imaging lacks sensitivity for AIDS associated cytomegalovirus encephalitis. Journal of NeuroVirology, 1996, 2, 397-403.	2.1	34
207	Neurologic opportunistic infections. Current Opinion in Neurology, 1995, 8, 175-178.	3.6	4
208	Level of Cytomegalovirus (CMV) DNA in Cerebrospinal Fluid of Subjects with AIDS and CMV Infection of the Central Nervous System. Journal of Infectious Diseases, 1995, 172, 527-531.	4.0	110
209	Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. Journal of Clinical Microbiology, 1995, 33, 1580-1583.	3.9	103
210	Concanavalin a enhances excitatory synaptic transmission in cultured rat hippocampal neurons. Synapse, 1993, 13, 94-97.	1.2	15
211	Blockade of ionotropic quisqualate receptor desensitization in rat hippocampal neurons by wheatgerm agglutinin and other lectins. Neuroscience, 1993, 52, 35-44.	2.3	12
212	Long-term potentiation during whole-cell recording in rat hippocampal slices. Neuroscience, 1993, 53, 39-47.	2.3	57
213	Electrophysiological properties of identified postnatal rat hippocampal pyramidal neurons in primary culture. Developmental Brain Research, 1993, 71, 19-26.	1.7	15
214	White matter lesions and cerebral atrophy on MR images in patients with and without AIDS dementia complex.. American Journal of Roentgenology, 1993, 161, 177-181.	2.2	44
215	Use of polymerase chain reaction to demonstrate cytomegalovirus DNA in CSF of patients with human immunodeficiency virus infection. Neurology, 1993, 43, 75-75.	1.1	49
216	Inhibition of long-term potentiation by NMDA-mediated nitric oxide release. Science, 1992, 257, 1273-1276.	12.6	226

#	Article	IF	Citations
217	Management of Neurologic Opportunistic Disorders in Human Immunodeficiency Virus Infection. Seminars in Neurology, 1992, 12, 28-33.	1.4	2
218	Low concentrations of inhibit the induction of long-term potentiation in rat hippocampal slices. Neuroscience Letters, 1992, 137, 245-248.	2.1	57
219	Nitric oxide inhibitors attenuate excitotoxicity in rat hippocampal slices. Neuroscience Letters, 1992, 135, 227-230.	2.1	183
220	Norepinephrine reverses inhibition of long-term potentiation in rat hippocampal slices. Neuroscience Letters, 1992, 142, 163-166.	2.1	21
221	Blockade of ionotropic quisqualate receptor desensitization by wheat germ agglutinin in cultured postnatal rat hippocampal neurons. Journal of Neurophysiology, 1992, 68, 1917-1929.	1.8	11
222	Wheat germ agglutinin enhances EPSCs in cultured postnatal rat hippocampal neurons by blocking ionotropic quisqualate receptor desensitization. Journal of Neurophysiology, 1992, 68, 1930-1938.	1.8	21
223	Nicotinic acetylcholine currents in cultured postnatal rat hippocampal neurons. Molecular Pharmacology, 1992, 41, 931-6.	2.3	72
224	2-Amino-3-phosphonopropionate blocks the induction and maintenance of long-term potentiation in rat hippocampal slices. Neuroscience Letters, 1991, 122, 187-190.	2.1	90
225	Characterization of quisqualate receptor desensitization in cultured postnatal rat hippocampal neurons. Journal of Neuroscience, 1991, 11, 3430-3441.	3.6	41
226	Ocular motor abnormalities in human immunodeficiency virus infection. Annals of Neurology, 1991, 30, 130-138.	5.3	22
227	Effects of bromowillardiine and willardiine on non-N-methyl-D-aspartate receptors in postnatal rat hippocampal neurons. Molecular Pharmacology, 1991, 40, 45-51.	2.3	8
228	Ototoxicity associated with dideoxycytidine. Lancet, The, 1990, 335, 1106.	13.7	24
229	Lithium enhances neuronal muscarinic excitation by presynaptic facilitation. Neuroscience, 1990, 38, 457-468.	2.3	23
230	Blockade of desensitization augments quisqualate excitotoxicity in hippocampal neurons. Neuron, 1990, 5, 61-66.	8.1	67
231	Serial studies of serum interleukin-2 in chronic progressive multiple sclerosis patients: occurrence of â€˜burstsâ€™ and effect of cyclosporine. Journal of Neuroimmunology, 1990, 28, 9-14.	2.3	21
232	Ketamine, Phencyclidine, and MKâ€801 Protect Against Kainic Acidâ€Induced Seizureâ€Related Brain Damage. Epilepsia, 1990, 31, 382-390.	5.1	201
233	Glycine antagonists block the induction of long-term potentiation in CA1 of rat hippocampal slices. Neuroscience Letters, 1990, 112, 251-256.	2.1	25
234	Neurological aspects of AIDS. Missouri Medicine, 1990, 87, 141-4.	0.3	0

#	Article	IF	Citations
235	Osmotic Demyelination Syndrome. Archives of Neurology, 1989, 46, 343.	4.5	30
236	Calcium influx through channels activates a potassium current in postnatal rat hippocampal neurons. Neuroscience Letters, 1989, 99, 293-299.	2.1	59
237	Complex responses activated by ibotenate in postnatal rat hippocampal neurons. Brain Research, 1989, 494, 193-197.	2.2	6
238	Convulsant Î³-butyrolactones block GABA currents in cultured chick spinal cord neurons. Brain Research, 1989, 484, 102-110.	2.2	7
239	Î±-Substituted thiobutyrolactones potentiate GABA currents in voltage-clamped chick spinal cord neurons. Neuroscience Letters, 1988, 87, 133-138.	2.1	13
240	Hyponatremia and the brain. American Family Physician, 1988, 38, 119-24.	0.1	1
241	The functional anatomy and pathology of lithium-pilocarpine and high-dose pilocarpine seizures. Neuroscience, 1987, 23, 953-968.	2.3	336
242	AIDS and the brain. American Family Physician, 1987, 36, 101-6.	0.1	27
243	Acute Effects of Lithium on Hippocampal Kindled Seizures. Epilepsia, 1985, 26, 689-692.	5.1	23
244	Acute effects of antidepressants on hippocampal seizures. Annals of Neurology, 1985, 18, 692-697.	5.3	31
245	Treatment of pain with antidepressants. American Family Physician, 1985, 31, 181-5.	0.1	14
246	Pain in Multiple Sclerosis. Archives of Neurology, 1984, 41, 1270-1272.	4.5	182
247	Seizures and pregnancy. American Family Physician, 1984, 29, 271-5.	0.1	2
248	Tetrahydrocannabinol for tremor in multiple sclerosis. Annals of Neurology, 1983, 13, 669-671.	5.3	170
249	Neurophysiologic effects of folate compounds in hippocampus, in vitro. Brain Research, 1983, 266, 209-216.	2.2	8
250	Thymectomy in multiple sclerosis. Two preliminary trials. Journal of Thoracic and Cardiovascular Surgery, 1983, 85, 88-93.	0.8	2
251	Progressive Multifocal Leukoencephalopathy in the Era of HAART. , 0, , 375-382.		1